Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 3rd.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Crinetics Pharmaceuticals Price Performance

Shares of CRNX stock traded down $0.19 on Friday, reaching $39.44. 761,028 shares of the company were exchanged, compared to its average volume of 1,264,711. The company has a market cap of $4.13 billion, a price-to-earnings ratio of -7.98 and a beta of 0.30. The company has a 50-day moving average of $40.56 and a 200-day moving average of $44.11. Crinetics Pharmaceuticals, Inc. has a one year low of $25.83 and a one year high of $57.99.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.08. Crinetics Pharmaceuticals had a negative net margin of 6,046.22% and a negative return on equity of 41.46%. The company had revenue of $6.16 million for the quarter, compared to analysts’ expectations of $4.32 million. During the same quarter in the prior year, the firm earned ($0.88) EPS. The business’s revenue was up NaN% on a year-over-year basis. As a group, sell-side analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.73 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CRNX. Wall Street Zen lowered shares of Crinetics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 target price on the stock in a report on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a report on Wednesday, January 21st. Lifesci Capital upgraded shares of Crinetics Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 13th. Finally, Citizens Jmp decreased their price objective on shares of Crinetics Pharmaceuticals from $105.00 to $96.00 and set a “market outperform” rating for the company in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $76.63.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. increased its stake in shares of Crinetics Pharmaceuticals by 12.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 4,679 shares of the company’s stock worth $218,000 after purchasing an additional 521 shares during the last quarter. Invesco Ltd. increased its stake in shares of Crinetics Pharmaceuticals by 76.8% during the 4th quarter. Invesco Ltd. now owns 158,089 shares of the company’s stock worth $7,359,000 after purchasing an additional 68,696 shares during the last quarter. ADAR1 Capital Management LLC increased its stake in shares of Crinetics Pharmaceuticals by 24.6% during the 4th quarter. ADAR1 Capital Management LLC now owns 309,368 shares of the company’s stock worth $14,401,000 after purchasing an additional 61,000 shares during the last quarter. Virtus Investment Advisers LLC increased its stake in shares of Crinetics Pharmaceuticals by 282.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,535 shares of the company’s stock worth $630,000 after purchasing an additional 9,998 shares during the last quarter. Finally, Progeny 3 Inc. purchased a new stake in shares of Crinetics Pharmaceuticals during the 4th quarter worth approximately $1,117,000. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Insider Activity at Crinetics Pharmaceuticals

In other news, insider Stephen F. Betz sold 10,612 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $396,570.44. Following the completion of the sale, the insider owned 137,101 shares in the company, valued at $5,123,464.37. This trade represents a 7.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Tobin Schilke sold 6,713 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $39.67, for a total transaction of $266,304.71. Following the sale, the chief financial officer owned 78,121 shares of the company’s stock, valued at approximately $3,099,060.07. The trade was a 7.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 142,380 shares of company stock worth $5,569,475 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.